Platinum-based chemotherapeutics such as cisplatin, carboplatin and oxaliplatin have been the mainstay of chemotherapy regimens for the treatment of many cancers for the last few decades. Nonetheless, clinical interest in new platinum agents appears to be waning with only a handful entering clinical trials recently. Till date, thousands of novel cytotoxic platinum complexes have been synthesized but only a few attain clinical relevance. This thesis highlights existing limitations of platinum drug design and proposes avenues for further exploration with focuses on molecularlytargeted platinum chemotherapeutics with novel mechanisms of action and on combined immuno-chemotherapeutic platinum agents. (Abstract shortened by UMI.)
|School:||National University of Singapore (Singapore)|
|School Location:||Republic of Singapore|
|Source:||DAI-B 77/06(E), Dissertation Abstracts International|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be